P hagocytic removal of apoptotic cells (efferocytosis) initiates a series of immunoregulatory events that include the expression of indoleamine 2,3 dioxygenase (IDO) and the cytokines IL-10 and TGF-β in myeloid cells and the recruitment of regulatory T cells [1] [2] [3] . However, when these regulatory processes are disrupted, apoptotic cells can induce substantial inflammation that can overcome tolerogenic mechanisms 1, 3 . Defects in mechanisms for the recognition and clearance of apoptotic cells or downstream tolerogenic pathways cause systemic autoimmunity in mice, generally with characteristics of systemic lupus erythematous (SLE). Similarly, genetic and experimental evidence suggests that altered clearance of apoptotic cells is a primary factor that drives disease in SLE [4] [5] [6] [7] .
AhR ('aryl hydrocarbon receptor') is a receptor and transcription factor that is important in xenobiotic metabolism 8 and serves a key function in immunity. After it is activated, AhR is released from a chaperone complex that anchors it in the cytoplasm [8] [9] [10] , then it translocates to the nucleus, driving transcriptional activity 9 . In immune cells, AhR has a dominant effect on phenotype by controlling the expression of cytokines, including IL-10, type I interferons, IL-12, IL-17 and TGF-β 9, [11] [12] [13] [14] [15] [16] [17] .
Here we present genetic and pharmacological evidence that DNA exposed by apoptotic cell death drove activation of AhR dependent on the pattern-recognition receptor TLR9 and downstream immunosuppression and immunotolerance. Mice with AhR deficiency in the myeloid lineage developed progressive pathology and autoimmunity reminiscent of SLE, and an AhR transcriptional signature was associated with human SLE. These observations identify a previously unknown role for AhR in selftolerance to apoptotic cells.
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that was not produced in Ahr −/− BMDMs co-cultured similarly (Fig. 1a ). Immunofluorescence and immunoblot analysis of BMDMs before exposure to apoptotic cells showed cytoplasmic AhR localization, while the addition of apoptotic cells induced a significant increase in nuclear AhR (Fig. 1b,c) . We observed a similar pattern of AhR-dependent expression of Cyp1a1 and Cyp1b1 mRNA in Ap-BMDCs ( Supplementary Fig. 1a ), which indicated that apoptotic cells induced AhR activity in efferocytic BMDMs and BMDCs.
Apoptotic cell-conditioned medium (Fig. 1d ) or culture of apoptotic cells in a Transwell system ( Supplementary Fig. 1b ) did not induce Cyp1a1 mRNA in BMDMs, which indicated that the activation of AhR by apoptotic cells required cell-cell contact. Moreover, 
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conditioned medium from Ap-BMDMs did not induce Cyp1a1 mRNA in BMDMs (Fig. 1d ), and inhibition of protein synthesis with cycloheximide did not affect the expression of Cyp1a1 mRNA ( Supplementary Fig. 1c ), which indicated that the apoptotic cells activated AhR through direct mechanism(s). Neither live cells nor necrotic cells induced AhR, and the ability to induce AhR in cells undergoing efferocytosis was acquired by 3 h after the induction of apoptosis ( Supplementary Fig. 1d,e ). Treatment of apoptotic cells with the pan-caspase inhibitor z-fad abolished phagocytosis and the induction of Cyp1a1 mRNA in Ap-BMDMs ( Supplementary  Fig. 1f,g) . Likewise, the treatment of apoptotic cells with annexin V for 30 min before co-culture (to mask phosphatidylserine), and the addition of cytochalasin D to Ap-BMDMs (to inhibit phagocytosis), prevented efferocytosis ( Supplementary Fig. 1f ) and significantly reduced the induction of Cyp1a1 mRNA in Ap-BMDMs relative to its induction in untreated (control) Ap-BMDMs (*P ≤ 0.05 and **P ≤ 0.01 (two-sided Student's t-test); Supplementary Fig. 1g ). Thus, apoptosis and dead-cell efferocytosis were required for the activation of AhR.
AhR modulates gene expression directly and indirectly, through epigenetic mechanisms 9, 18 . Analysis of BMDMs by the assay for transposase-accessible chromatin followed by high-throughput sequencing (ATAC-seq) 19 showed that efferocytosis drove largescale changes in active chromatin, with the detection of 2,736 regions that were differentially accessible in Ap-BMDMs relative to their accessibility in resting BMDMs ('differentially accessible regions' (DARs)) ( Fig. 1e ). In contrast, addition of the AhR inhibitor CH223191 20 to Ap-BMDMs caused a modest change in active chromatin relative to the chromatin in Ap-BMDMs without the addition of CH223191, with only 230 unique DARs and 247 shared DARs in CH223191-treated Ap-BMDMs versus Ap-BMDMs without inhibition of AhR (Fig. 1e) ; however, changes were generally concordant between Ap-BMDMs with inhibition of AhR and those without inhibition of AhR ( Fig. 1e ), which suggested that AhR had a weak effect on chromatin accessibility in Ap-BMDMs.
In Ap-BMDMs purified by flow cytometry after 8 h of co-culture, analysis by RNA-based next-generation sequencing (RNAseq) showed altered expression of 4,498 transcripts in Ap-BMDMs 
Ahr -/-IL-6 (ng/ml) IL-10 (pg/ml) IL-6 (ng/ml) IL-10 (pg/ml) Fig. 1a . b, Chromatin-immunoprecipitation analysis of the interaction of AhR with AhREs in the promoters of various genes in BMDMs and Ap-BMDMs (key) cultured for 3 h as in Fig. 1a ; results are presented relative to that of input material (before immunoprecipitation) from control (unstimulated) BMDMs. c,d, ELISA of cytokines in supernatants of Ap-BMDMs cultured in the presence or absence (key) of neutralizing IgG antibody to (anti-) IL-10 or IL-6 (c) or in the presence of recombinant (r) IL-10 or IL-6 (d). Each symbol represents an individual replicate; small horizontal lines indicate the mean ( ± s.d.). NS, not significant (P > 0.05); *P ≤ 0.05 and **P ≤ 0.01 (two-sided Student's t-test). Data are representative of four experiments with similar results, with n = 4 (a,c,d) or n = 3 (b) biologically independent samples per group.
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relative to their expression in resting BMDMs (with a false-discovery rate (FDR) of < 0.05 and a change in expression of over 0.75fold (upregulation or downregulation)) ( Fig. 1f ). Among these, the most significant change in expression was in genes encoding molecules with immunoregulatory function (for example, Il10) or linked to AhR responsiveness (for example, Cyp1b1 and Ereg (which encodes encoding epiregulin)) ( Fig. 1f ). Addition of the AhR inhibitor CH223191 altered the expression of 59 genes in Ap-BMDMs relative to their expression in resting BMDMs ( Fig. 1g ) but did not affect the basal expression of mRNA. Ingenuity pathway analysis showed that inhibition of AhR shifted the mRNA profile of Ap-BMDMs from one associated with homeostasis pathways to one associated with inflammation and cellular recruitment ( Supplementary Fig. 2 ). Accordingly, transcript heat maps indicated the downregulation of mRNA encoding molecules associated with immunoregulatory polarization (for example, Il10 and Arg1) and increased expression of transcripts encoding molecules associated with inflammation (including Il12p40, Il6 and Tnfs4 (which encodes the T cell-costimulatory molecule OX40L) in Ap-BMDMs in which AhR was inhibited ( Fig. 1h ,i). These data suggested that AhR drove efferocytosis-dependent regulatory polarization in BMDMs. ELISA showed that Ahr −/− Ap-BMDMs had significantly lower expression of IL-10 protein than that of wild-type Ap-BMDMs but had higher expression of the proinflammatory cytokines IL-1β , IL-6, IL-12p40 and TNFα ( Fig. 2a ). Because AhR modulates the promoter activity of both Il10 and Il6 in myeloid cells 18, 21 , we used chromatin immunoprecipitation to assess its binding to AhRresponsive elements (AhREs) in Ap-BMDMs. The association of AhR with AhREs was enriched 13-fold in the Cyp1a1 promoter and 7-fold in the Il10 promoter in Ap-BMDMs, relative to its association in resting BMDMs (Fig. 2b ). We did not detect any association of AhR with AhREs in the promoters of genes encoding molecules that regulate the expression of proinflammatory cytokines in either Ap-BMDMs or resting BMDMs (Fig. 2b) . Because IL-10 has a key role in limiting inflammation and is induced rapidly in vivo in response to efferocytosis 2 , we investigated whether AhR modulated the polarization of Ap-BMDMs by inducing IL-10. Antibody neutralization of IL-10 increased IL-6 and IL-12p40 protein in wild-type Ap-BMDMs ( Fig. 2c ). Neutralization of IL-10 
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NATuRE IMMuNoLogy had no effect on Ahr −/− Ap-BMDMs ( Fig. 2c ), which suggested a lack of IL-10 production in Ahr −/− BMDMs after efferocytosis, while the addition of recombinant IL-10 inhibited the production of IL-6 and IL-12p40 in Ahr −/− Ap-BMDMs ( Fig. 2d ), which indicated that supplementation with IL-10 was able to restore regulatory responses. In contrast, manipulation of the activity of IL-6 by the addition of neutralizing antibodies or recombinant IL-6 had no effect on the production of IL-10 or IL-12p40 in Ap-BMDMs ( Fig. 2c,d) . Thus, the engulfment of apoptotic cells drove the rapid induction of AhR-dependent transcription of the gene encoding IL-10 in BMDMs, which had a key role in the polarization of BMDMs following efferocytosis.
Apoptotic cells activate AhR through a TLR9-dependent mechanism.
Because AhR responds to diverse ligands generated downstream of IDO-dependent tryptophan metabolism, including kynurenines 12, 13 , we measured expression of the gene encoding IDO (Ido1) and IDO activity (i.e., kyurenine production) in Ap-BMDMs. We did not detect any change in Ido1 mRNA ( Supplementary  Fig. 3a ) or increased kynurenine production in Ap-BMDMs 
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( Supplementary Fig. 3b ) relative to that in BMDMs. Moreover, we observed (by semi-quantitative PCR (sqPCR) analysis) induction of Cyp1a1 mRNA in Ap-BMDMs treated with the IDO inhibitor 1MT ( Supplementary Fig. 3c ) and in Ido1 −/− Ap-BMDMs ( Supplementary  Fig. 3c ), which suggested that the activation of AhR in Ap-BMDMs was independent of IDO. Because DNA exposed on apoptotic blebs has been shown to induce expression of IL-10 in splenic B cells 22 , we investigated whether DNA from apoptotic cells could activate AhR in BMDMs. Pretreatment of apoptotic cells with DNAse 22 before co-culture with BMDMs abolished the induction of AhR ( Fig. 3a ) and its nuclear accumulation ( Fig. 3b ) in Ap-BMDMs and reduced the induction of IL-10 relative to its induction control Ap-BMDMs (generated with apoptotic cells not pretreated with DNAse) (Fig. 3c ). The latter effect was overcome by addition of the AhR agonist ITE to Ap-BMDMs in which the apoptotic cells were pretreated with DNAse ( Fig. 3c ). Similar pretreatment of the apoptotic cells with RNAse did not affect the induction of Cyp1a1 mRNA in Ap-BMDMs ( Fig. 3a) , while the addition of chloroquine to Ap-BMDMs reduced the expression of Cyp1a1 in Ap-BMDMs ( Fig. 3a ), which indicated that acidification of lysosomes was required for the activation of AhR. Because TLR9 is the main sensor of DNA in the lysosome, we assessed the requirement for TLR9 in the induction of AhR in Ap-BMDMs. Tlr9 −/− BMDMs did not show nuclear accumulation 
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of AhR after efferocytosis (Fig. 3d ), and both Tlr9 −/− Ap-BMDMs and Ap-BMDMs treated with the TLR9 antagonist IRS 869 23 had significantly less induction of Cyp1a1 mRNA than that of wildtype, untreated Ap-BMDMs ( Fig. 3e and Supplementary Fig. 3d ). Inhibition of the RNA sensor TLR7 with the oligonucleotide antagonist IRS 661 24 did not affect the expression of Cyp1a1 mRNA ( Supplementary Fig. 3d ), which suggested that RNA in apoptotic cells did not drive AhR's activity in Ap-BMDMs. Furthermore, Tlr9 −/− Ap-BMDMs showed reduced expression of IL-10 and increased expression of proinflammatory cytokines (Fig. 3f ), and that expression was restored by addition of the AhR agonist ITE to Ap-BMDMs ( Fig. 3f ). These data indicated that the apoptotic cell-driven activation of Ahr and subsequent production of IL-10 required the recognition, by TLR9, of DNA from apoptotic cells.
AhR is required for efferocytosis-driven immunosuppression.
Because the intravenous administration of syngeneic apoptotic cells induces the expression of IL-10 and TGF-β in splenic macrophages and DCs in mice 2,3 , we next investigated whether AhR suppressed responses to apoptotic cells in vivo. For this, we studied B6.Ahr fl/fl LysM-Cre +/− mice, which have myeloid lineage-specific deletion of AhR (called 'LysM-AhR cKO mice' here) and their Ahr fl/fl LysM-Cre −/− (control) littermates. We challenged these mice intravenously with B6 thymocytes made apoptotic by irradiation and assessed cytokine production in whole-spleen lysates at 18 h after cell administration. While we detected a significant increase in the expression of IL-10 and TGF-β protein in splenic lysates of the control littermates after injection of apoptotic thymocytes (Fig. 4a ), there was a significant increase in IL-6 and IL-12p40 protein, but no induction of IL-10 or TGF-β , in the LysM-AhR cKO mice ( Fig. 4a ). Next we sorted SignR1 + marginal-zone macrophages, CD169 + metallophillic macrophages and F4/80 + red-pulp macrophages and CD11c + DC populations sub-fractionated on the basis of their expression of CD8α , CD103 and B220 1-3 ( Supplementary Fig. 4a ) at 8 h after intravenous injection of apoptotic cells into mice as described above, then quantified the transcripts from Cyp1a1, Il10, Tgfb1, Il6 and Il12b. We found robust induction of Cyp1a1 mRNA ( > 18-fold) and Il10 mRNA in F4/80 + CD11cred-pulp macrophages from wild-type mice but not in those from LysM-AhR cKO mice, after injection of apoptotic cells (Fig. 4b ). Likewise, Tgfb1 mRNA was elevated in CD11c + CD8α + CD103 + DCs from wildtype mice but not in those from LysM-AhR cKO mice (Fig. 4b) . In contrast, F4/80 + CD11cred-pulp macrophages and CD169 + F4/80metallophillic macrophages from LysM-AhR cKO mice showed higher expression of Il6 and Il12b mRNA than that of such cells from their control littermates, after the administration of apoptotic cells (Fig. 4b ). After intravenous injection of apoptotic cells, the expression of Cyp1a1 and Il10 mRNA was upregulated similarly in Ido1 −/− F4/80 + CD11cred-pulp macrophages and their wild-type counterparts (Fig. 4c,d ), in agreement with the lack of IDO expression after efferocytosis in these cells 1 . These data indicated that AhR attenuated the induction of proinflammatory cytokines, through a pathway independent of IDO, following the intravenous administration of apoptotic cells to mice. IL-10 production by macrophages and DCs suppresses autoimmune T cell reactivity in EAE 25 , and lack of induction of IL-10 in 
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splenic macrophages is associated with the population expansion of proinflammatory T cells reactive to apoptotic-cell antigens 1, 26 . Thus, we investigated whether AhR was needed to suppress effector T cell responses to apoptotic antigens. We labeled OT-II T cells (which have transgenic expression of a T cell antigen receptor specific for an epitope of ovalbumin (OVA) amino acids 323-339) with the division-tracking dye CFSE and adoptively transferred 2 × 10 6 of the OT-II cells intravenously into C57BL/6 (B6) mice pretreated with 
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the Ahr antagonist CH223191, then challenged the recipient mice with OVA-expressing apoptotic thymocytes from Act-mOVA mice, which express membrane-bound OVA driven by the promoter of the chicken gene encoding β -actin 2 . There was no proliferation of CFSE-labeled OT-II T cells in B6 mice that received OVA-expressing apoptotic thymocytes plus OT-II T cells or in B6 mice that received OT-II T cells only (Fig. 4e) . In contrast, 55% of the CSFE-labeled OT-II T cells had divided in B6 mice that received OVA-expressing apoptotic thymocytes and the AhR inhibitor CH223191 (Fig. 4e ), which suggested that AhR was needed for the suppression of effector T cell responses to antigens derived from apoptotic cells. Chronic intravenous administration of apoptotic cells does not elicit autoimmunity in wild-type mice 26, 27 . However, deletion of splenic macrophages with clodronate liposomes triggers the development of autoantibodies to DNA and chromatin in response to the intravenous injection of apoptotic cells 26 . To determine whether AhR controlled the induction of autoimmunity after chronic exposure to apoptotic cells, we intravenously injected syngeneic apoptotic cells (in which apoptosis was induced by irradiation) into LysM-AhR cKO mice weekly for 4 weeks. While their control littermates did not show a change in the serum concentration of immunoglobulin G (IgG) antibodies to double-stranded DNA (dsDNA) relative to the concentration of such antibodies at baseline, LysM-AhR cKO mice showed a 60-fold higher concentration of IgG antibodies to dsDNA than the concentration at baseline (Fig. 4f ). Systemic administration of apoptotic cells induces allograft tolerance 3 . Thus, we challenged female LysM-AhR cKO mice and their control littermates intravenously with apoptotic thymocytes from male B6 mice (B6-Ap cells), followed by transplantation of skin grafts from male B6 mice 7 d later. The control recipient littermates that did not receive B6-Ap cells rejected the skin grafts, with a mean survival time of 36 d (Fig. 4g ). While the intravenous administration of B6-Ap cells resulted in 100% graft survival for 50 d in the control littermates 2,3 , such administration of B6-Ap cells to LysM-AhR cKO mice resulted in mean graft survival time of 32 d (Fig. 4g ), which indicated that myeloid AhR function was required for apoptotic cell-induced allograft tolerance.
Administration of dexamethasone induces substantial intrathymic thymocyte death followed by clearance by thymus-resident phagocytes 28, 29 . We used this model to assess the effect of AhR on the immune responses to cell death in B6 and LysM-AhR cKO mice. At 24 h after dexametasone administration, we observed a 20-fold reduction in the overall thymus cellularity for B6 mice with or without administration of CH223191 and for LysM-AhR cKO mice ( Supplementary Fig. 5a ) and significant induction of Cyp1a1, Il10 and Tgfb1 mRNA in the thymus homogenates of B6 mice (Fig. 4h) . In contrast, the induction of such mRNA was decreased in LysM-AhR cKO mice or B6 mice treated with CH223191, along with increased expression of Il6 and Il12b (Fig. 4h) . These results suggested that AhR was required as part of a general tissue response to apoptotic cells.
Manipulation of AhR modulates autoimmunity in lupus.
Because resident phagocytes have a key role in limiting autoimmune disease 26 , we investigated whether modulation of AhR affected the development of autoimmunity. B6.Fcgr2b −/− (B6 mice that lack expression of the IgG Fc receptor Fcγ RIIB; called 'R2B mice' here) and MRL lpr mice (mice of the MRL-MpJ strain with the lymphoproliferation (lpr) mutation) are prone to develop autoimmunity reminiscent of SLE 30 . sqPCR analysis showed higher expression of Cyp1a1 mRNA in splenic F4/80 + macrophages and CD11c + CD8α + and CD11c + CD8α -DCs in R2B and MRL lpr mice than its basal expression in macrophages and DCs from age-and sex-matched B6 and MRL-MpJ (control) mice ( Fig. 5a and Supplementary Fig. 5b ). In particular, CD8α + DCs and F4/80 + macrophages in R2B and MRL lpr mice showed much higher expression of Cyp1a1 mRNA than that of such cells from B6 and MRL-MpJ (control) mice ( Fig. 5a and Supplementary Fig. 5b ). Metabolites of IDO activity or metabolites derived from the gut microbiome are endogenous activators of AhR 12, 13, 21, 31 , and expression of IDO1 protein is higher in the spleen of R2B and MRL lpr mice than in that of B6 and MRL-MpJ mice 1,2 . Ido1 mRNA was expressed mainly in CD11c + B220 + splenic plasmacytoid DCs (pDCs) in R2B and MRL lpr mice ( Supplementary  Fig. 5c,d ). However, there was no higher expression Cyp1a1 mRNA in pDCs from R2B and MRL lpr than in pDCs from B6 and MRL-MpJ (control) mice ( Fig. 5a and Supplementary Fig. 5b ). Moreover, treatment of R2B mice with broad-spectrum antibiotics to diminish the intestinal microbiota did not affect Cyp1a1 mRNA in CD8α + DCs or F4/80 + macrophages ( Supplementary Fig. 5d ), which suggested that AhR's activity was independent of microbial metabolites in this context. We next assessed the effect of AhR on autoimmune pathology in 24-week-old R2B mice. Administration of the AhR antagonist CH223191 significantly increased splenomegaly in R2B mice, while the AhR agonist ITE reduced the total number of splenocytes by 40%, relative to that of untreated R2B mice (Fig. 5b) . Inhibition of AhR significantly increased the frequency of F4/80 + macrophages and pDCs in R2B mice, relative to that of untreated R2B mice, while the frequency of CD8α + or CD8α -DCs was not different from that of untreated R2B mice (Fig. 5b) . In contrast, treatment of R2B mice with ITE significantly reduced the frequency of F4/80 + macrophages, CD8α -DCs and B220 + pDCs relative to that of untreated R2B mice (Fig. 5b ). Moreover, CH223191 increased the frequency of activated CD24 lo splenic B cells in R2B mice relative to their frequency in untreated R2B mice, while ITE reduced the frequency of CD24 lo B cells and CD44 hi CD4 + and CD44 hi CD8 + T cells ( Supplementary Fig. 6a,b) . The frequency of IL-10 + F4/80 + spleen macrophages was lower in R2B mice than in age-matched B6 mice, while the frequency of IL-6 + and TNF + macrophages was higher (Fig. 5c ); treatment with CH223191 further increased the frequency of IL-6 + and TNF + macrophages, while ITE significantly increased the frequency of IL-10 + macrophages (Fig. 5c ). 24-weekold female R2B mice had a higher serum titer of IgG anti-nuclear antibodies (ANAs) than that of B6 mice ( Supplementary Fig. 6c ). The administration of CH223191 further increased the serum titer of ANAs and antibodies to dsDNA and histone ( Fig. 5d and Supplementary Fig. 6c,d) , renal deposition of IgG and IgM and periglomerular accrual of macrophages ( Fig. 5e ) and exaggerated kidney pathology ( Supplementary Fig. 6e ), relative to such parameters in untreated R2B mice, while ITE had the opposite effect (Fig. 5d,e and Supplementary Fig. 6c-e ). Accordingly, CH223191 significantly increased albuminuria in R2B mice, while ITE significantly reduced it, relative to albuminuria in untreated R2B mice (Fig. 5f ). Finally, CH223191-treated R2B mice showed 100% death by 28 weeks (Fig. 5g) , while ITE-treated mice showed 100% survival at 45 weeks (Fig. 5g ), compared with 100% mortality at 41 weeks for untreated R2B mice. To investigate whether activation of AhR by other means had a protective effect, we treated 30-week-old R2B mice with established disease with the AhR pro-agonist I3C (indole-3-carbinol) 32, 33 or its downstream metabolite DIM (3,3-diindolylmethane) 34, 35 . A 4-week course of either I3C or DIM significantly reduced serum concentration of IgG antibodies to dsDNA and abolished proteinuria (Fig. 5h ). These results indicated that manipulation of AhR's activity was able to prevent disease development and reverse established autoimmune pathology.
LysM-AhR cKO mice develop systemic autoimmunity with age.
As AhR is known to limit inflammatory pathology [12] [13] [14] 17, 31 , we next investigated whether homeostatic AhR activity was needed to limit spontaneous autoimmunity. 12-week-old female LysM-AhR cKO mice showed no evidence of autoimmunity; however, aged (62-week-old) female LysM-AhR cKO mice showed prominent Articles NATuRE IMMuNoLogy homogenous ANA staining patterns (Fig. 6a ) and a higher concentration of IgG antibodies to dsDNA and histones than that of their age-and sex-matched control littermates (Fig. 6b ), which suggested that loss of AhR drove the autoimmunity. Aged female LysM-AhR cKO mice had a twofold greater number of splenocytes than that of their age-matched control littermates (Fig. 6c) , with a greater number of CD24 lo B cells, CD44 hi CD4 + and CD44 hi CD8 + T cells, CD86 + F4/80 + macrophages and CD86 + CD8α + DCs (Fig. 6c ), suggestive of chronic stimulation; however, there was no population expansion of CD86 + pDCs in LysM-AhR cKO mice relative to the abundance of such cells in their control littermates (Fig. 6c ). Aged female LysM-AhR cKO mice exhibited greater renal pathology than that of their control littermates (Fig. 6d) , and immunofluorescence analysis of the kidneys showed greater deposition of IgG, IgM and complement in LysM-AhR cKO mice than in their control littermates ( Fig. 6e) , although there was no evidence of proteinuria. These data indicated that AhR activity in myeloid cells was required for peripheral tolerance and the prevention of spontaneous autoimmunity.
Human SLE is associated with an AhR signature. Next we sought to determine whether AhR had a function in humans similar to that described above for mice. We used peripheral blood mononuclear cell (PBMC) samples from patients with SLE (with active disease or in remission) and compared them with those from healthy donors ( Supplementary Tables 1-3 ). sqPCR indicated significantly higher expression of IFNB1 mRNA in patients with SLE than in healthy control subjects, although there was no differences between the two groups of patients with SLE ( Fig. 7a ). Patients with SLE had an AhR transcriptional signature (i.e., AHR, CYP1A1 and IL10), with higher expression of those genes than that of healthy control subjects (Fig. 7a) ; however, only CYP1A1 expression was higher in patients with active disease than in patients in remission (Fig. 7a) . We then used qPCR to assess the activation of AhR in CD4 + T cells, CD8 + T cells, HLA-DR + CD14 + monocytes, HLA-DR + CD14 -CD11c + CD123conventional DCs (cDCs), and HLA-DR + CD14 -CD11c -CD123 + CD303 + pDCs sorted from freshly collected blood samples of patients with active SLE or healthy control subjects ( Supplementary Fig. 4b and Supplementary Table 4 and 5). While we did not detect macrophages in the circulation (data not shown), the expression of AHR mRNA was tenfold higher in CD11c + cDCs and CD14 + monocytes than in T cells or CD123 + CD303 + pDCs in general (Fig. 7b ). CD11c + cDCs from patients with SLE had an AhR transcriptional signature as described above, while CD123 + CD303 + pDCs from patients with SLE had significantly higher expression of CYP1A1 mRNA, but not of AHR or IL10 mRNA, than that of healthy control subjects (Fig. 7b) .
To determine if efferocytosis modulated the activation of Ahr in human myeloid cells, we cultured PBMC-derived macrophages (PBDMs) with apoptotic Jurkat human T cells (made apoptotic by irradiation or by 6 h of culture with staurosporine), to generate ' Ap-PBDMs' . We observed higher expression of CYP1A1 and CYP1B1 mRNA (by sqPCR) and of IL-10 protein (by ELISA) in Ap-PBDMs following 8 h of culture than in PBDMs cultured without apoptotic Jurkat T cells, regardless of the mode by which the apoptosis was induced ( Fig. 7c and Supplementary Fig. 7a ). Inhibition of AhR via the addition of CH223191 to the co-culture medium or treatment of the apoptotic Jurkat T cells with DNAse before co-culture abolished the enhanced expression of CYP1A1 mRNA and production of IL-10 noted above and increased IL-6 and TNFα in Ap-PBDMs relative to their abundance in untreated Ap-PBDMs (Fig. 7c,d and Supplementary Fig. 7b ), which indicated that the apoptotic cells activated the AhR pathway in human PBDMs in a DNA-dependent manner.
To identify potential AhR-activating factors in patients with SLE, we used HPLC to analyze the plasma of patients with SLE and healthy control subjects ( Supplementary Tables 1-3 ). The AhR agonists I3C, DIM and indole were not detected, while IPA (indole-3-propionic acid) was detected in all samples, with a lower concentration in patients with SLE than in healthy control subjects ( Supplementary Fig. 7c ). Healthy control subjects and patients with SLE in remission exhibited a similar concentration of the IDOtryptophan metabolite kynurenine, while patients with active SLE showed a slightly, but not significantly, higher serum concentration of kynurenine ( Supplementary Fig. 7c ); this indicated that the amount of AhR agonists in the plasma did not correlate with the AhR signatures observed in samples from patients with SLE and healthy subjects and suggested that other factors might contribute to AhR's activity.
As circulating microparticles with some characteristics of apoptotic cells can be found in the plasma of patients with SLE 36 , we investigated whether these microparticles might function as AhR agonists in patients with SLE. Microparticles were present at a similar concentration in plasma from patients with SLE and that from healthy control subjects ( Supplementary Fig. 7d ), and they had a diameter of 100-400 nm and morphology typical of extracellular vesicles, as indicated by electron microscopy ( Supplementary  Fig. 7e ). In both patients with SLE and healthy control subjects, these microparticles were positive for the tetraspanin CD9, the intracellular vesicle protein CD63 and the human leukocyte antigen HLA-ABC, although we detected intra-group variability in the expression of those markers in both the patients with SLE and healthy control subjects, while HLA-DR was not detected ( Supplementary Fig. 7f ). As previously described 36 , microparticles from both patients with SLE and healthy control subjects expressed the endothelial marker CD31 ( Supplementary Fig. 7g ), indicative of an endothelial origin, with microparticles from some patients expressing CD66b ( Supplementary Fig. 7g ), a marker usually assigned to neutrophils. However, microparticles from the plasma of patients with SLE showed higher expression of phosphatidylserine than that of microparticles from the plasma of healthy control subjects 36 (Fig. 7e ) and uniquely exhibited DNA on the membrane (Fig. 7e) , as indicated by staining with the DNA-binding dye DAPI.
When incubated with PBDMs, microparticles from the plasma of patients with SLE induced expression of CYP1A1 and IL10 mRNA in the PBDMs, while microparticles from the plasma of healthy control subjects did not (Fig. 7f ). Treatment of PBDMs with the AhR blocker CH223191 reduced the production of IL-10 and increased the expression of IL6 2.5-fold ( Fig. 7f and Supplementary  Fig. 7h ). In addition, DNase treatment of microparticles from the plasma of patients with SLE abolished the induction of CYP1A1 and IL10 mRNA in PBDMs (Fig. 7g) , which indicated that DNA in the microparticles induced the activation of AhR in the PBDMs. Thus, apoptotic cells and DNA-containing microparticles activated AhR in human PBMC-derived macrophages, and this was required for the induction of IL10 and restriction of proinflammatory cytokine production triggered by the phagocytosis of apoptotic cells.
Discussion
Tolerance to apoptotic cells is needed to maintain physiological homeostasis and prevent autoimmunity. In this study, we found that phagocytosis of apoptotic cells triggered the activation of AhR in mouse macrophages and DCs, which in turn restricted inflammatory responses to apoptotic cells by inducing the immunoregulatory cytokine IL-10. AhR was also required for apoptotic cell-driven tolerogenic polarization of human macrophages. Thus, the data presented here have identified a role for AhR in suppressing inflammatory immunity toward apoptotic cells and in attenuating the pathogenesis of systemic autoimmune disease.
AhR binds to motifs in both the Il10 promoter and the Il6 promoter; however, in the context of efferocytosis, AhR seemed to interact directly with regulatory elements in the Il10 locus and did Articles NATuRE IMMuNoLogy not bind to the promoters of genes encoding inflammatory cytokines. While AhR interacts with multiple transcription factors and acts as a bridge between 5′ enhancers and downstream promoter elements 37 , the lack of large-scale changes in either the extent of open chromatin or the transcriptome in macrophages would suggest that AhR has a specific effect on the production of regulatory cytokines.
We found that the activation of AhR in macrophages was dependent on phagocytosis and the presence of DNA and on TLR9. Deletion of TLR9 has been shown to accelerate the onset of disease pathology and mortality in MRL lpr mice 38 . On the basis of our observations, it is plausible that loss of or a reduction in the activation of AhR in Tlr9 −/− mice might contribute to accelerated disease, which would suggest that under certain circumstances, innate sensors might be requisite for immunoregulation. DNA exposed to the extracellular environment is rapidly degraded by extracellular DNAse in circulation; however, in patients with SLE, DNA is protected by autoantibodies that mask it and probably aid in its uptake by phagocytes 39 . Similarly, DNA exposed in apoptotic cells is rapidly opsonized by natural IgM and complement 40 , which promotes phagocytosis and the anti-inflammatory effects of apoptotic cells. Thus, we speculate that protection of the DNA and opsonized uptake is required for the functional effects observed for apoptotic cells or microparticles in vivo.
Microparticles serve a key role in cellular communication by facilitating the intercellular transfer of material and information. Our results showed that microparticles from patients with SLE activated AhR in human PBMC-derived macrophages, in a manner dependent on DNA. This suggests that apoptotic microparticles might regulate immunity systemically, dampening inflammation in chronic inflammatory diseases such as SLE. While our analysis was limited to microparticles in the circulation, it is likely that a similar process might occur in tissues. Thus, we would predict that tissueresident phagocytes function locally to promote tolerance to dying cells in situ.
Our data indicated that AhR is a key molecular regulator of inflammation in the pathways involved in disposal of apoptotic cells in vivo. In mice, apoptotic cells induced mRNA encoding inflammatory cytokines in macrophages from LysM-AhR cKO mice and led to autoimmune reactivity. Moreover, we detected an enhanced AhR-related transcriptional signature in patients with SLE, which indicated that this anti-inflammatory pathway might be upregulated during autoimmunity to restrict pathology. The expression of Cyp1a1 mRNA was not higher in pDCs from R2B mice than in those from age-matched B6 control mice, despite higher expression of Ido1 than that of B6 mice; however, the expression of CYP1A1 mRNA was significantly higher in pDCs from patients with SLE than in those from healthy control subjects. Mouse AhR and human AhR bind to some of their ligands with different affinity 41, 42 . Thus, it is possible that the production of IDO and metabolites of the gut microbiome might affect the activity of AhR differently in mouse pDCs versus human pDCs. In particular, AhR interacts with the bacterially produced tryptophan derivative indirubin with tenfold higher affinity in humans than in mice 41, 42 . Thus, it is possible that human pDCs might be more sensitive than mice pDCs to the effects of IDO and gut microbiome-derived ligands, which resulted in the higher CYP1A1 expression observed in pDCs from patients with SLE than in pDCs from healthy control subjects. Nevertheless, our data indicated that the phagocytosis of apoptotic cells directly induced AhR activity by a mechanism independent of IDO in both mouse macrophages and human macrophages. In conclusion, our report has identified an AhR-dependent mechanism of immunotolerance to self and provides not only new insights into the molecular control of peripheral tolerance but also new 'druggable' targets for therapeutic intervention in systemic autoimmune disease.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-018-0107-1.
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Methods
Mice. C57BL/6 J (B6), B6.Ahr −/− , B6.LysMCre, B6.Ido1 −/− , B6.Act-mOVA-II (Act-mOVA), B6.OT-II + Thy1.1 + , B6.Fcgr2b −/− , B6.Ahr flox/flox , MRL lpr and MRL-MpJ mice were bred and maintained in specific pathogen-free conditions at the Princess Margaret Cancer Center animal facilities. Female mice between 8 and 12 weeks of age were used unless otherwise noted. All animal procedures were followed as per the University Health Network Institutional Animal Care and Use Committee guidelines. For animal and human studies, there was no randomization of animal allocation or blinding during analysis and all samples were included (i.e., none were excluded).
SLE samples.
Patients with SLE who satisfied four or more of the revised 1997 American College of Rheumatology classification criteria for SLE 43 were recruited from the University of Toronto Lupus Clinic; they provided full, informed consent according to UHN institutional guidelines. Blood and clinical data were obtained that enabled the calculation of disease activity using the SLE disease activity index (SLEDAI-2K) 44 . Patients with active SLE (defined as a clinical SLEDAI-2K of > 0; i.e., not including the complement and anti-dsDNA components of the SLEDAI-2K) had SLEDAI-2K scores of 4-32 (mean, 13.5; Supplementary Table 1 ), and patients with quiescent SLE had SLEDAI scores of 0-4 (derived from low serum complements and/or high anti-dsDNA levels alone; mean, 1.8; Supplementary  Table 2 ). Control blood samples were obtained from healthy donors with no family history of SLE (Supplementary Table 3 ). In one set of experiments, we collected fresh blood from patients with active SLE (as defined above Supplementary Table 4 ) or healthy control subjects (Supplementary Table 5 ). PBMCs were isolated by Percoll gradient (GE Healthcare Life Sciences) and were stained for flow cytometry sorting as described elsewhere in Methods. The study was approved by the Research Ethics Board of UHN, with participants providing informed consent. Total RNA was isolated from blood archived in PAXgene tubes, collected at the time of a regular follow-up visit, using the PAXgene Blood RNA Kit (Qiagen) with modifications to improve RNA yield and quality, addition of RNAse inhibitor, an off-column DNAse I digestion and final ethanol precipitation.
Culture of macrophages and DCs. Resident macrophages were obtained from 6-to 8-week-old female mice by peritoneal lavage with 3 ml ice-cold PBS and were cultured in RPMI 1640 plus 10% FBS (FBS), and 100 U/ml penicillin and streptomycin (ThermoFisher).
To generate mouse bone marrow-derived macrophages and DCs, femurs and tibias were harvested from 6-to 8-week-old female mice. Bone marrow was flushed from the cavity, and single-cell suspensions were generated and cultured in DMEM supplemented with 40 ng/ml MCSF for macrophages or 20 ng/ml GM-CSF for DCs, (Peprotech) 10% FBS (FBS), and 100 U/ml penicillin and streptomycin. After 7 d, greater than 90% of the cells in the MCSF cultures were F4/80 + CD11b + macrophages, as determined by cytometry analysis. GM-CSF cultures generate a mixed population of macrophages and DCs 45 . Thus, to isolate DCs, we collected non-adherent cell fractions at day 7 and sorted (by flow cytometry) the CD11C + CD11b int MHCII hi cells representing the DC population 45 .
To generate human macrophages, PMBCs from healthy donors (obtained from the Princess Margaret Cancer Center blood donor center) were cultured in the monocyte attachment media and were incubated for 2 h at 37 °C. Nonadherent cells were removed with extensive washes with PBS, and adherent cells were cultured in M2-macrophage generation medium as per the manufacturer's instructions (PromoCell). After 10 d, the differentiated macrophages were characterized by flow cytometry and used in experiments.
Generation of apoptotic cells and co-culture.
Thymuses from 4-to 6-week-old mice were collected, and single-cell suspensions were exposed to 40 Gy of radiation in a Gammacell irradiator, followed by 6 h of incubation at 37 °C in RPMI 1640 plus 1% BSA (Sigma). For apoptosis of Jurkat T cells (clone E6-1, ATCC), cells were treated with 5 μ M staurosporine (Sigma) at 37 °C in RPMI 1640 plus 1% BSA for 6 h or were exposed to 100 Gy of radiation in a Gammacell irradiator, followed by culture as described above. In both cases, cells were extensively washed with PBS before use. Flow cytometry revealed that > 85% thymocytes were apoptotic and < 1% were necrotic, as determined by annexin V and propidium iodine staining. For some experiments, a Transwell co-culture system (Costar) was used to prevent direct contact of macrophages with apoptotic cells. In some experiments, macrophages were pretreated with the AhR antagonist CH223191 (Sigma-Aldrich) dissolved in DMSO at 5 μ M for 2 h.
To remove nucleic acids from apoptotic blebs before co-culture they were treated as previously described 22 . In brief, apoptotic cells were treated for 1 h with DNAse (Roche) at 50 μ g/ml dissolved in a storage buffer (20 mM Tris-HCl and 1 mM MgCl 2 , pH 7.5) or RNAse (Sigma) at 50 μ g/ml dissolved in water. After incubation, cells were washed extensively with ice-cold PBS plus 1%BSA to remove any residual enzyme.
In some experiments, macrophage-apoptotic cell co-cultures were supplemented with IgG antibody to (anti-) IL-10 at 1 μ g/ml (Clone JES5-2A5, eBioscience), recombinant IL-10 at 100 ng/ml (R&D Systems), anti-IL-6 at 1 μ g/ml (Clone MP5-20F3, eBioscience) and recombinant IL-6 at 1 μ g/ml (R&D Systems). To assess the requirement for the IDO pathway in Cyp1a1 induction, macrophage-apoptotic cell cultures were pretreated with the IDO1 inhibitor 1-methyl-D-tryptophan at 200 μ M (Sigma), and measurements of kynurenine and tryptophan ratio were done using HPLC as previously described 46 .
sqPCR. RNA from sorted cells was purified using RNeasy mini kit (Qiagen), and 250 ng of RNA was reverse-transcribed using a random hexamer cDNA reverse transcription kit (Clontech). For sqPCR, 1 μ l of cDNA was amplified using primers for genes tested. Detailed information about the primers used is in Supplementary Tables 6 and 7 . Demographic information for clinical samples used for RNA analysis of healthy human controls and patients with lupus is in Supplementary Tables 1-3 . iQ SYBR Green Supermix (Bio-Rad) was used for sqPCR, and amplification was recorded on an iQ5 real-time PCR detection system (Bio-Rad). A typical two-step real time PCR protocol per the manufacturer's instructions was performed (39 cycles of 10 s at 95 °C and 30 s at 60 °C, followed by thermal dissociation step for the SYBR green detection). Results were analyzed with the accompanying software according to the manufacturer's instructions.
RNA sequencing analysis. RNA samples were quantified by qubit (Life Technologies), and an Agilent Bioananlyzer assessed the RNA quality. All samples had RIN above 8. Libraries were prepared using TruSeq Stranded mRNA kit (Illumina). 200 ng of total RNA were purified for poly(A) tail-containing mRNA molecules using poly(T) oligo-attached magnetic beads; following purification, RNA was fragmented. The cleaved RNA fragments were copied into first-strand cDNA using reverse transcriptase and random primers. That was followed by second-strand cDNA synthesis using RNAse H and DNA polymerase I. A single ' A' base was added and ligated to the adaptor, followed by purification and enrichment with PCR to create cDNA libraries. Final cDNA libraries were size validated using an Agilent Bioanalyzer, and concentration was validated by qPCR. All libraries were normalized to 10 nM and were pooled together. Pooled libraries were further diluted to 2 nM and were denatured with 0.2 N NaOH. 1.7 pM of pool libraries were loaded onto a Nextseq cartridge for cluster generation and were sequenced by Pair-end 75 cycles V2 using Illumina Nextseq500 to achieve a minimum of ~35 × 10 6 reads per sample.
A total of 1,325,194,544 sequencing reads were obtained in the four conditions, with each condition sequenced as a biological triplicate. After de-multiplexing and initial quality control, all sequencing reads were aligned against the mouse genome reference sequence GRCm38 with STAR v2.5.1a 47 . We used the inherited 5′ trimming method of STAR as well as the inherited read counting. The entire command was as follows: STAR-outFilterMismatchNoverLmax 0.05-outFilterType BySJout-outSAMstrandField intronMotif-outSAMattributes NH HI AS nM NM MD XS-outSAMmapqUnique 60-quantMode GeneCounts-outFilterIntronMotifs RemoveNoncanonical-outFilterMultimapNmax 1-clip5pNbases 13-sjdbGTFfile $GRCm38.ensembl85.gtf. Read counts were measured for gene annotations downloaded from Ensembl Genes V85 48 . This resulted in a total of 990,489,880 (74.74%) of overall reads mapping as pairs to annotated genes. Next, inter-sample normalization for read counts was applied with edgeR 49 , which resulted in counts per million (CPM). After filtering for genes with low expression (log CPM > 0 across all three replicates of at least one condition), normalized read counts were used for a differential gene expression analysis again using edgeR. We corrected for multiple testing, reporting the false-discovery rate (FDR). All sequencing data was deposited at the European Nucleotide Archive (ENA), accession number PRJEB19473.
ATAC-seq.
To determine the chromatin accessibility, ATAC-seq was performed 19 . In brief, 30,000 live macrophages treated as indicated were washed with PBS and were lysed for 5 min on ice (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 and 0.1% IGEPAL CA-630). After isolation of crude nuclei, samples were treated for 30 min at 37 °C with Tn5 transposase, which binds to the open chromatin of the cell, and the DNA was purified by a MinElute PCR Purification Kit. Transposed DNA fragments were amplified using specific adapters, followed by purification with MinElute PCR Purification Kit. Fragments of 240-360 bp were selected in a PippinHT system. The quality of the library and its DNA concentration were assessed by Bioanalyzer instruments and were ultimately submitted for sequencing using Illumina HiSeq 2500 sequencer, V4 chemistry. Bowtie2 was used to align fastq files to mm10, and samtools was used to remove duplicates, sort and index BAM files. ENSEMBL annotations for transcription start sites and FANTOM5 annotations for enhancers were used to identify windows of interest (TSS ± 250 bp) for read counting, and bedtools multibamcov was used to retrieve read counts per sample per window. Limma-trend was used to identify significant Differentially Accessible Regions (DARs) at an FDR of < 0.1 for all pairwise comparisons between conditions. Ingenuity Pathway analysis (IPA). Pathway analysis was performed using QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN). We determined enrichment of DE genes between BMDMs versus Ap-BMDMs and between Ap-BMDMs plus CH223191 versus Ap-BMDMs (change in expression of 0.75-fold (log values) (upregulation or downregulation); FDR ≤ 0.05) in IPA canonical pathways as well as in IPA diseases and functions.
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For sorting of human samples, PBMC fractions were divided into two groups: for monocytic cell enrichment, the PBMCs were stained with APC-labeled antibodies to lineage markers (anti-CD56 (clone NCAM16.2), anti-CD19 (clone HIB19) and anti-CD3 (clone UCHT1)), to remove T cells, B cells and natural killer cells, and with antibodies to markers for DCs, pDC, and monocytes (anti-CD11c (clone B-Ly6), anti-CD123 (clone 7G3), anti-CD11b (clone ICRF44), anti-HLA-DR (clone G46-6), anti-BDCA-2/CD303 (clone V24-785) and anti-CD14 (clone 61D3) (all from BD Biosciences). For T cell enrichment, the PBMC fraction was stained with anti-CD4 (clone RPA-T4), anti-CD8 (clone SK1) and anti-CD3 (clone SK7) (all from BD Biosciences). All cells were sorted on a Dako Cytomation MoFlo cell sorter into tubes containing RNA protect reagent (Qiagen).
Flow cytometry.
Single-cell suspensions from spleens and kidneys were prepared. At least 1 × 10 6 cells were stained with fluorophore-conjugated anti-F4/80 (clone BM8, Biolegend), anti-CD11c (clone N418, Biolegend), anti-CD8α (clone 53-6.7, Biolegend), anti-CD4 (clone GK1.5, Biolegend), anti-CD86 (clone GL1, BD Biosciences), anti-MHCII (clone M5/114.15.2, eBiosciences), anti-CD44 (clone IM7, BD Biosciences), anti-CD24 (clone M1/69, Biolegend), anti-B220 (clone RA3-6B2, eBiosciences), anti-CD23 (clone B3B4, BD Biosciences), anti-CD21/ CD35 (clone 7G6, BD Biosciences) and anti-CD103 (clone 2E7, Biolegend). For intracellular cytokine staining, single-cell suspensions of spleens from B B6.R2b −/− or MRL lpr mice were incubated with brefeldin A solution and monensin (eBioscience) for 2 h with shaking at 37 °C. Cells were fixed and permeabilized using an intracellular staining kit (eBioscience) and were stained with fluorophoreconjugated anti-IL-10 (clone JES5-16E3, eBioscience), anti-IL-6 (clone MP5-20F3, BD Biosciences), anti-TNF (clone MP6-XT22, BD Biosciences) and anti-F4/80 (clone BM8, Biolegend). For flow cytometry, ≥ 1 × 10 5 events (1 × 10 6 events, for adoptive transfer OT-II cells) were collected on a LSR II flow cytometer, and all results were analyzed with FlowJo software (TreeStar).
To examine effector T cell responses to apoptotic cell-associated antigens, 2 × 10 5 CD45.2 + CD4 + OT-II T cells labeled with 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) (Invitrogen) were adoptively transferred intravenously into CD45.1 + B6 mice. The next day, mice were challenged intravenously with 1 × 10 7 membrane-bound OVA-expressing apoptotic thymocytes from Act-mOVA mice. After 3 d, spleens were harvested and assessed for the proliferation of adoptively transferred OT-II T cells by staining with anti-CD45.2 (clone 104, eBioscience) and anti-CD4 (BD Pharmingen), followed by flow cytometry.
Skin transplantation. Female recipient mice were given intravenous injection of 1 × 10 7 apoptotic cells from male mice. 1 week later, tail skin (~1 cm 2 ) from male donor mice was placed onto the left thoracic flank region of female mice, as previously described 3 . After 7-10 d, bandages were removed and allografts were assessed for signs of rejection for 50 d. Grafts were considered rejected when ulceration and/or necrosis was evident in > 80% of the graft as previously reported 3 .
Microparticle analysis.
Plasma from patients with active lupus or healthy control subjects was centrifuged at 500 g for 10 min at 4 °C. Supernatants were collected and centrifuged at 20,800 g for 10 min at 4 °C. The pellet was washed twice with PBS containing 1% BSA.
Isolated microparticles corresponding to 2 ml of original plasma from healthy control subjects and patients with active SLE were bound to 4-µ m aldehydesulfate latex beads (Molecular Probes), coupled with mouse anti-human CD9 (Clone HI9a; BioLegend), under gentle rotating agitation at room temperature overnight, as previously described 52 . The microparticle-bead complexes were then stained with phycoerythrin-conjugated antibodies specific for CD9 (Clone M-L13; BD Biosciences), CD63 (Clone H5C6; eBioscience), HLA-ABC (Clone W6/32; BioLegend) and HLA-DR (Clone L243; BioLegend), CD31 (clone WM59; BioLegend), CD45 (clone 2D1; BioLegend), CD66b (clone G10F5; BioLegend), CD19 (clone HIB19; BioLegend), CD3 (clone UCHT1; BioLegend), annexin V (Cat.640920 BioLegend) and DAPI (Thermo) and were assessed using flow cytometry and the corresponding isotype-matched control antibodies (MOPC-21 for IgG1k and MOPC-173 for IgG2a, all from BioLegend).
For electron microscopy analysis, microparticle preparations from plasma samples from healthy control subjects and patients with active SLE were subjected to electron microscopy with negative ion capture. In brief, an aliquot of 3 µ l from each sample was added to a grid with a glow discharged carbon-coated supporting film for 3 min. The excess solution was soaked off by a filter paper, and the grid was rinsed by adding 5 µ l distilled water for 10 s, and water was then soaked off by a filter paper. The grid was stained with 5 µ l 1% uranyl acetate in water for 7 s. Excess stain was soaked off by a filter and the grid was air-dried. The samples were examined in a Hitachi HT 7700 electron microscope (Hitachi) at 80 kV, and digital images were taken by a Veleta camera (Olympus).
Image and statistical analysis. For all in vitro studies using expression of Cyp1a1 or Il10 after exposure to apoptotic cells, the power of the comparison was 100% using n = 3 samples per condition. Likewise, using cytokine data for splenic IL-10 protein production after injection of apoptotic cells, the power for the comparison was 100% using n = 5 per group. Thus, these numbers were used for experiments unless otherwise noted. For survival studies, the power of the comparison was 100% using n = 10 mice per group.
Image analysis was done using National Institutes of Health Image-J software unless otherwise indicated. Means, s.d., unpaired Student's t-test, Wilcoxon ranksum test, and one-way ANOVA were used to analyze the data using Prism V6 software (GraphPad Software). When comparing two groups, a P value of ≤ 0.05 was considered to be significant. Survival data for animals or skin allografts were analyzed with Kaplan-Meier survival plots, followed by the log-rank test. 
nature research | life sciences reporting summary
Life Sciences Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1. Sample size
Describe how sample size was determined.
For all in vitro studies, using Cyp1a1 or Il10 expression after apoptotic cell exposure the power of the comparison was 100% using n=3 samples per condition. Likewise, using cytokine data for splenic IL-10 protein production after apoptotic cell injection the power for the comparison was 100% using n=5/group. Thus these numbers were used for experiments unless otherwise noted. For survival studies the power of the comparison was 100% using n=10 mice/group.
Data exclusions
Describe any data exclusions.
All data was included, there was no exclusion
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All experiments were repeated at least 2 times, with most being repeated 3-4 times. Always with similar results (i.e. all findings were reproducible).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For animal and human studies there was no randomization of animal allocation
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For animal and human studies there was no blinding with the exception of pathologic assessment of kidney pathology which was scored in a blinded manner. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. Describe the software used to analyze the data in this study.
Image analysis was done using National Institutes of Health Image-J software. Statistics were analyzed using Prism© V6 software (GraphPad Software Inc). Flow cytometry data was analyzed with FlowJo software (TreeStar) For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
There are no restrictions on availability of proprietary materials and all commercially acquired reagents are duly noted in the report. b. Describe the method of cell line authentication used. The only cell line used was jurkat T cells ordered directly from ATCC immediately prior to use.
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These cells are rigorously authenticated by ATCC usingmorphology, karyotyping, and PCR based approaches to confirm the identity of human cell lines and to rule out both intra-and interspecies contamination. These include an assay to detect species specific variants of the cytochrome C oxidase I gene (COI analysis) to rule out inter-species contamination and short tandem repeat (STR) profiling to distinguish between individual human cell lines and rule out intra-species contamination. c. Report whether the cell lines were tested for mycoplasma contamination.
Cells were negative for mycoplasma.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
Jurkat was not listed in the most current ICLAC list.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
C57BL/6J (B6), B6.Ahr-/-, B6.LysMCre, B6.Ido1-/-, B6.Act-mOVA-II (Act-mOVA), B6.OTII +Thy1.1+, B6.Fcgr2b-/-, B6.Ahrflox/flox, MRLlpr, and MRL-MpJ mice were bred and maintained in specific pathogen free conditions at the Princess Margaret Cancer Center animal facilities. Female mice between 8-12 weeks of age were used unless otherwise noted. All animal procedures were followed as per the University Health Network Institutional Animal Care and Use Committee guidelines.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants. SLE patients, satisfying 4 or more of the revised 1997 American College of Rheumatology classification criteria for SLE, were recruited from the University of Toronto Lupus Clinic under full, informed consent according to UHN institutional guidelines. Blood and clinical data were obtained enabling calculation of disease activity using the SLE disease activity index (SLEDAI-2K) 45 . Active patients (defined as a clinical SLEDAI-2K > 0, ie. not including the complement and anti-dsDNA Ab components of the SLEDAI-2K) had SLEDAI-2K scores from 4 to 32, and quiescent patients had SLEDAI scores from 0 to 4 (derived from low serum complements and/or high anti-dsDNA Ab levels alone, mean 1.8). Control blood samples were obtained from healthy donors with no family history of SLE. In one set of experiments we collected fresh blood from active SLE patients or healthy controls . The study was approved by the Research Ethics Board of UHN with participants providing informed consent.
